[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002002597A3 - Peptide extended glycosylated polypeptides - Google Patents

Peptide extended glycosylated polypeptides Download PDF

Info

Publication number
WO2002002597A3
WO2002002597A3 PCT/DK2001/000459 DK0100459W WO0202597A3 WO 2002002597 A3 WO2002002597 A3 WO 2002002597A3 DK 0100459 W DK0100459 W DK 0100459W WO 0202597 A3 WO0202597 A3 WO 0202597A3
Authority
WO
WIPO (PCT)
Prior art keywords
glycosylated polypeptides
polypeptide
interest
peptide extended
peptide
Prior art date
Application number
PCT/DK2001/000459
Other languages
French (fr)
Other versions
WO2002002597A2 (en
Inventor
Jens Sigurd Okkels
Anne Dam Jensen
Den Hazel Bart Van
Original Assignee
Maxygen Aps
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2000/000743 external-priority patent/WO2001049830A2/en
Priority claimed from PCT/DK2001/000090 external-priority patent/WO2001058493A1/en
Application filed by Maxygen Aps, Maxygen Holdings Ltd filed Critical Maxygen Aps
Priority to AU2001267337A priority Critical patent/AU2001267337A1/en
Priority to CA002412882A priority patent/CA2412882A1/en
Priority to EP01944987A priority patent/EP1299535A2/en
Priority to JP2002507849A priority patent/JP2004504016A/en
Publication of WO2002002597A2 publication Critical patent/WO2002002597A2/en
Publication of WO2002002597A3 publication Critical patent/WO2002002597A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01015—Polygalacturonase (3.2.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y602/00—Ligases forming carbon-sulfur bonds (6.2)
    • C12Y602/01—Acid-Thiol Ligases (6.2.1)
    • C12Y602/01003—Long-chain-fatty-acid-CoA ligase (6.2.1.3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Glycosylated polypeptides comprising the primary structure NH2-X-Pp-COOH wherein X is a peptide addition comprising or contributing to a glycosylation site, and Pp is a polypeptide of interest or comprising the primary structure NH2-Px-X-Py-COOH, wherein Px is an N-terminal part of a polypeptide Pp of interest, Py is a C-terminal part of said polypeptide Pp, and X is a peptide addition comprising or contributing to a glycosylation site. The glycosylated polypeptides having improved properties as compared to the polypeptide of interest.
PCT/DK2001/000459 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides WO2002002597A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001267337A AU2001267337A1 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides
CA002412882A CA2412882A1 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides
EP01944987A EP1299535A2 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides
JP2002507849A JP2004504016A (en) 2000-06-30 2001-06-29 Peptide-extended glycosylated polypeptides

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200001027 2000-06-30
DKPA200001027 2000-06-30
DKPA200001092 2000-07-14
DKPA200001092 2000-07-14
PCT/DK2000/000743 WO2001049830A2 (en) 1999-12-30 2000-12-29 Improved lysosomal enzymes and lysosomal enzyme activators
DKPCT/DK00/00743 2000-12-29
PCT/DK2001/000090 WO2001058493A1 (en) 2000-02-11 2001-02-09 Conjugates of follicle stimulating hormones
DKPCT/DK01/00090 2001-02-09

Publications (2)

Publication Number Publication Date
WO2002002597A2 WO2002002597A2 (en) 2002-01-10
WO2002002597A3 true WO2002002597A3 (en) 2002-06-27

Family

ID=56290160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2001/000459 WO2002002597A2 (en) 2000-06-30 2001-06-29 Peptide extended glycosylated polypeptides

Country Status (5)

Country Link
EP (1) EP1299535A2 (en)
JP (1) JP2004504016A (en)
AU (1) AU2001267337A1 (en)
CA (1) CA2412882A1 (en)
WO (1) WO2002002597A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023173B (en) * 2004-03-25 2012-08-08 埃欧金生物制品公司 Modified xylanases exhibiting improved expression

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
CN102180944A (en) 2001-10-10 2011-09-14 诺和诺德公司 Remodeling and glycoconjugation of peptides
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
EP1515986B1 (en) * 2002-06-17 2018-10-24 Chr. Hansen A/S Improved method of producing an aspartic protease in a recombinant host organism
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
CN102212019B (en) 2003-03-14 2015-05-27 蔚所番有限公司 Branched water-soluble polymers and their conjugates
US7691603B2 (en) 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
ES2380093T3 (en) 2003-05-09 2012-05-08 Biogenerix Ag Compositions and methods for the preparation of human growth hormone glycosylation mutants
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
AU2004293103C1 (en) 2003-11-24 2010-12-02 Ratiopharm Gmbh Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2552892C (en) 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
EP1745141B2 (en) 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-linked glycoforms of faktor vii and method to manufacture them
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
PL2586456T3 (en) 2004-10-29 2016-07-29 Ratiopharm Gmbh Remodeling and glycopegylation of fibroblast growth factor (FGF)
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
KR101608083B1 (en) 2005-01-25 2016-04-01 씨티아이 바이오파마 코포레이션 Conjugates of biologically active proteins having a modified in vivo half-life
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP1746161A1 (en) * 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007111496A1 (en) * 2006-03-28 2007-10-04 Universiteit Utrecht Holding B.V. Improved carbohydrate recognition domains
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
AR063975A1 (en) * 2006-11-28 2009-03-04 Centelion FC FUSIONS WITH RECEIVER FOR FGF SOLUBLE MODIFIED WITH IMPROVED BIOLOGICAL ACTIVITY
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
DK2173890T3 (en) 2007-06-21 2011-06-27 Univ Muenchen Tech Biologically active proteins with increased stability in vivo and / or in vitro
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP5769142B2 (en) * 2007-09-04 2015-08-26 独立行政法人酒類総合研究所 Method for high secretion of heterologous proteins in Pichia yeast
MX2010009154A (en) 2008-02-27 2010-09-09 Novo Nordisk As Conjugated factor viii molecules.
JP2010183885A (en) * 2009-02-13 2010-08-26 Kobe Univ Method for producing protein and expression vector used therefor
JP5828889B2 (en) 2010-05-21 2015-12-09 エクスエル‐プロテイン ゲーエムベーハー Biosynthesis of proline / alanine random coil polypeptides and uses thereof
KR101901467B1 (en) 2010-11-08 2018-11-02 아미쿠스 세라퓨틱스, 인코포레이티드 Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity
WO2015073727A1 (en) * 2013-11-13 2015-05-21 Aequus Biopharma, Inc. Engineered glycoproteins and uses thereof
MX368656B (en) 2013-12-20 2019-10-10 Hoffmann La Roche Improved recombinant polypeptide production methods.
WO2015091130A1 (en) * 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Method for improving the recombinant production of soluble fusion polypeptides
MY180297A (en) 2015-06-24 2020-11-27 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
RU2753390C1 (en) 2015-10-02 2021-08-13 Ф. Хоффманн-Ля Рош Аг Bispecific antibodies to human cd20/human transferrin receptor and methods for their use
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
BR112019015482A2 (en) * 2017-01-31 2020-03-31 Regenxbio Inc. METHOD FOR TREATING A HUMAN INDIVIDUAL DIAGNOSED WITH MUCOPOLYSACARIDOSIS I (MPS I)
KR20240063170A (en) 2017-07-06 2024-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
TWI835747B (en) 2017-09-22 2024-03-21 賓州大學委員會 Gene therapy for treating mucopolysaccharidosis type ii

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1990007573A1 (en) * 1988-12-23 1990-07-12 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1990007573A1 (en) * 1988-12-23 1990-07-12 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
WO1999013081A1 (en) * 1997-09-08 1999-03-18 Akzo Nobel N.V. EXPRESSION OF GONADOTROPINS IN $i(DICTYOSTELIUM)
WO1999054342A1 (en) * 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CANTOR ALAN B ET AL: "Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 32, 1992, pages 23357 - 23363, XP002173975, ISSN: 0021-9258 *
DOEBBER T W ET AL: "ENHANCED MACROPHAGE UPTAKE OF SYNTHETICALLY GLYCOSYLATED HUMAN PLACENTAL BETA GLUCO CEREBROSIDASE", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 257, no. 5, 1982, pages 2193 - 2199, XP001002183, ISSN: 0021-9258 *
FULLER MARIA ET AL: "Receptor mediated binding of two glycosylation forms of N-acetylgalactosamine-4-sulphatase.", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1406, no. 3, 28 April 1998 (1998-04-28), pages 283 - 290, XP001002494, ISSN: 0006-3002 *
FURBISH F S ET AL: "UPTAKE AND DISTRIBUTION OF PLACENTAL GLUCO CEREBROSIDASE IN RAT HEPATIC CELLS AND EFFECTS OF SEQUENTIAL DEGLYCOSYLATION", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 673, no. 4, 1981, pages 425 - 434, XP001002396, ISSN: 0006-3002 *
MURRAY G J ET AL: "TARGETING OF SYNTHETICALLY GLYCOSYLATED HUMAN PLACENTAL GLUCOCEREBROSIDASE", BIOCHEMICAL MEDICINE, vol. 34, no. 2, 1985, pages 241 - 246, XP001042190, ISSN: 0006-2944 *
WARREN CHARLES E: "Glycosylation.", CURRENT OPINION IN BIOTECHNOLOGY, vol. 4, no. 5, 1993, pages 596 - 602, XP001042143, ISSN: 0958-1669 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023173B (en) * 2004-03-25 2012-08-08 埃欧金生物制品公司 Modified xylanases exhibiting improved expression

Also Published As

Publication number Publication date
WO2002002597A2 (en) 2002-01-10
CA2412882A1 (en) 2002-01-10
EP1299535A2 (en) 2003-04-09
AU2001267337A1 (en) 2002-01-14
JP2004504016A (en) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2002002597A3 (en) Peptide extended glycosylated polypeptides
CY1112228T1 (en) MODIFIED KUNITZ PROPERTY POLICY
WO2001000666A3 (en) Self-aligning peptides derived from human elastin and other fibrous proteins
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
EP2253645A3 (en) Factor VIII Polypeptide
CA2155185A1 (en) Totally synthetic affinity reagents
CA2168011A1 (en) Hybrid toxin
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
WO2002002621A3 (en) Mammalian secreted proteins
WO2001071005A3 (en) Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
WO1998005685A3 (en) Self-aligning peptides derived from elastin and other fibrous proteins
WO1999003881A3 (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
WO2002006306A3 (en) SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY
AU4415796A (en) Production of c-terminal amidated peptides from recombinant protein constructs
WO2004094592A3 (en) Polymer-conjugated glycosylated neublastin
WO2000058465A3 (en) Flint polypeptide analogs
CA2077590A1 (en) Recombinant dna coding for a protein with endochitinase activity
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU8727001A (en) A novel polypeptide-tumor suppressor protein 63 and the polynucleotide encoding said polypeptide
WO2002036154A3 (en) Procollagen (iii) propeptides and related substances for treating fibrotic diseases
AU8750601A (en) A novel polypeptide, a scan zinc-finger protein subfamily protein 57 and the polynucleotide encoding the polypeptide
AU9538501A (en) A novel polypeptide-mouse transient receptor potential protein 2 (trp2)12 and the polynucleotide encoding said polypeptide
AU2001233567A1 (en) A novel polypeptide, human protein 9 of short-chain scorpion toxin and the polynucleotide encoding the polypeptide
FR2787454B1 (en) TOPOISOMERASE II INHIBITOR

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001944987

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001267337

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2412882

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 54/CHENP/2003

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2001944987

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001944987

Country of ref document: EP